Aurinia rises as regulators clarify path for voclosporin

Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) said it believes results from a planned Phase III study and a completed Phase IIb study of voclosporin (LX211) will be sufficient for regulatory submissions in the EU and Japan. The company based its plans on discussions with EMA and Japan's Pharmaceutical and Medical Devices Agency. The company said last year it believed the two trials would support an NDA submission, based on its discussions with FDA.

On Friday, Aurinia gained C$0.60 to C$9.44 in Toronto and $0.46 to $7.05 on NASDAQ. It reported the update after market close Thursday...